-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, at the 17th European Crohn's and Colitis Organization (ECCO) Congress in 2022, Eli Lilly announced for the first time data from a Phase 3 clinical program of the novel anti-inflammatory drug mirikizumab in the treatment of moderate to severe ulcerative colitis (UC)
Results presented at the meeting showed a statistically higher rate of clinical remission in the mirikizumab group compared to the placebo group at week 12 (p=0.
UC is a chronic inflammatory disease of the large intestine (also known as the colon) that affects the lining of the colon and can lead to the formation of small sores or ulcers
Mirikizumab, a humanized IgG4 monoclonal antibody that targets the p19 subunit that binds IL-23, is currently in development for a variety of immune diseases, including plaque psoriasis (PsO), ulcerative colon inflammation (UC), Crohn's disease (CD),
The phase 3 clinical program LUCENT of mirikizumab in the treatment of UC includes a total of 3 studies, namely LUCENT-1, LUCENT-2 (NCT03524092), and LUCENT-3 (NCT03519945)
Additional treatments are still needed to relieve UC patients from their most challenging symptoms
A total of 1162 patients were enrolled in the LUCENT-1 study, including those who had not received prior biologic-naive therapy and those who had previously received a biologic-experienced (biologic-experienced) ) but treatment failure in refractory patients
The results showed: (1) At the 12th week of treatment, 24.
At week 12, 45.
As early as within 2 weeks of treatment and continuing through Week 12, mirikizumab-treated patients had a statistically significant reduction in the 11-point bowel emergency severity score
The overall safety profile of mirikizumab in this study was similar to previous studies in UC and consistent with other anti-IL-23p19 antibodies in other therapeutic areas
Note: The original text has been deleted
Original source: Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study
